Protection from Group B Streptococcal Infection in Neonatal Mice by Maternal Immunization with Recombinant Sip Protein

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2002 Aug 17

PMID 12183534

Citations 23

Authors

Denis Martin

Stephane Rioux

Edith Gagnon

Martine Boyer

Josee Hamel

Nathalie Charland

Bernard R Brodeur

Affiliations

Soon will be listed here.

Abstract

The protective potential of antibodies directed against group B streptococcus (GBS) Sip surface protein was determined by using the mouse neonatal infection model. Rabbit Sip-specific antibodies administered passively to pregnant mice protected their pups against a GBS lethal challenge. In addition, active immunization with purified recombinant Sip protein of female CD-1 mice induced the production of specific antibodies that also confer protection to the newborn pups against GBS strains of serotypes Ia/c, Ib, II, III, and V. These data confirm that Sip-specific antibodies can cross the placenta and conferred protective immunity against GBS infections.

Citing Articles

Bioinformatics analysis to design a multi-epitope mRNA vaccine against S. agalactiae exploiting pathogenic proteins.

Barazesh M, Abbasi M, Mohammadi M, Nasiri M, Rezaei F, Mohammadi S Sci Rep. 2024; 14(1):28294.

PMID: 39550419 PMC: 11569170. DOI: 10.1038/s41598-024-79503-y.

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines.

Duan H, Huang W, Lv Q, Liu P, Li Q, Kong D Vaccines (Basel). 2024; 12(6).

PMID: 38932301 PMC: 11209137. DOI: 10.3390/vaccines12060573.

CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog.

Furuta A, Coleman M, Casares R, Seepersaud R, Orvis A, Brokaw A PLoS Pathog. 2023; 19(6):e1011490.

PMID: 37384812 PMC: 10337943. DOI: 10.1371/journal.ppat.1011490.

Development and evaluation of a multi-epitope subunit vaccine against group B infection.

Zhang Y, Liang S, Zhang S, Zhang S, Yu Y, Yao H Emerg Microbes Infect. 2022; 11(1):2371-2382.

PMID: 36069613 PMC: 9543083. DOI: 10.1080/22221751.2022.2122585.

Bacterial and Host Determinants of Group B Streptococcal Vaginal Colonization and Ascending Infection in Pregnancy.

Brokaw A, Furuta A, Dacanay M, Rajagopal L, Adams Waldorf K Front Cell Infect Microbiol. 2021; 11:720789.

PMID: 34540718 PMC: 8446444. DOI: 10.3389/fcimb.2021.720789.

References

Kasper D, Baker C, Baltimore R, Crabb J, Schiffman G, Jennings H . Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med. 1979; 149(2):327-39. PMC: 2184812. DOI: 10.1084/jem.149.2.327. View

Wessels M, Paoletti L, Rodewald A, Michon F, DiFabio J, Jennings H . Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993; 61(11):4760-6. PMC: 281231. DOI: 10.1128/iai.61.11.4760-4766.1993. View

Baker C, Kasper D . Group B streptococcal vaccines. Rev Infect Dis. 1985; 7(4):458-67. DOI: 10.1093/clinids/7.4.458. View

Baker C, Rench M, Edwards M, Carpenter R, Hays B, Kasper D . Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988; 319(18):1180-5. DOI: 10.1056/NEJM198811033191802. View

Lagergard T, Shiloach J, Robbins J, Schneerson R . Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid. Infect Immun. 1990; 58(3):687-94. PMC: 258520. DOI: 10.1128/iai.58.3.687-694.1990. View

Wessels M, Paoletti L, Kasper D, Difabio J, Michon F, Holme K . Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990; 86(5):1428-33. PMC: 296886. DOI: 10.1172/JCI114858. View

Paoletti L, Kasper D, Michon F, DiFabio J, Jennings H, Tosteson T . Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 1992; 89(1):203-9. PMC: 442838. DOI: 10.1172/JCI115564. View

Rodewald A, Onderdonk A, WARREN H, Kasper D . Neonatal mouse model of group B streptococcal infection. J Infect Dis. 1992; 166(3):635-9. DOI: 10.1093/infdis/166.3.635. View

Paoletti L, Wessels M, Rodewald A, Shroff A, Jennings H, Kasper D . Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994; 62(8):3236-43. PMC: 302951. DOI: 10.1128/iai.62.8.3236-3243.1994. View

10.

Madoff L, Paoletti L, Tai J, Kasper D . Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994; 94(1):286-92. PMC: 296308. DOI: 10.1172/JCI117319. View

11.

Wessels M, Paoletti L, PINEL J, Kasper D . Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995; 171(4):879-84. DOI: 10.1093/infdis/171.4.879. View

12.

Kasper D, Paoletti L, Wessels M, Guttormsen H, Carey V, Jennings H . Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996; 98(10):2308-14. PMC: 507681. DOI: 10.1172/JCI119042. View

13.

Paoletti L, PINEL J, Rodewald A, Kasper D . Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. J Infect Dis. 1997; 175(5):1237-9. DOI: 10.1086/593678. View

14.

Schuchat A . Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev. 1998; 11(3):497-513. PMC: 88893. DOI: 10.1128/CMR.11.3.497. View

15.

Baker C, Paoletti L, Wessels M, Guttormsen H, Rench M, Hickman M . Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1998; 179(1):142-50. DOI: 10.1086/314574. View

16.

Glezen W, Alpers M . Maternal immunization. Clin Infect Dis. 1999; 28(2):219-24. DOI: 10.1086/515122. View

17.

Lachenauer C, Kasper D, Shimada J, Ichiman Y, Ohtsuka H, Kaku M . Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999; 179(4):1030-3. DOI: 10.1086/314666. View

18.

Gravekamp C, Kasper D, Paoletti L, Madoff L . Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun. 1999; 67(5):2491-6. PMC: 115995. DOI: 10.1128/IAI.67.5.2491-2496.1999. View

19.

Paoletti L, PINEL J, Kennedy R, Kasper D . Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J Infect Dis. 2000; 181(2):653-8. DOI: 10.1086/315285. View

20.

Baker C, Paoletti L, Rench M, Guttormsen H, Carey V, Hickman M . Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000; 182(4):1129-38. DOI: 10.1086/315839. View